

## AC Immune to Host Webinar Highlighting its Innovative Morphomer™ Technology Platform and Pipeline

*Therapeutic and diagnostic Morphomers™ enable AC Immune's unique precision medicine approach for neurodegenerative diseases*

*Webinar will take place on Wednesday, March 31, 2021 at 10:00 AM ET*

**Lausanne, Switzerland, March 26, 2021** – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that it will host a corporate update webinar on Wednesday, March 31<sup>st</sup> at 10:00 AM ET until 11:30 AM ET.

During the webinar, members of the AC Immune Management and Research and Development Teams will discuss the unique benefits of the Company's innovative Morphomer™ technology platform, which accelerates the design, synthesis, and development of CNS-optimized, conformation-specific small molecules directed against pathological proteins. The platform has produced multiple clinically validated therapeutic and diagnostic candidates that bind selectively to target proteins intracellularly, at the earliest stages of disease.

The current Morphomer™ pipeline includes two clinical-stage diagnostic candidates (Tau-PET tracer and alpha-synuclein-PET tracer), and one therapeutic candidate that has completed Phase 1 (Morphomer™ Tau ACI-3024). Additional first-in-class Morphomer™-derived therapeutic and diagnostic candidates targeting Tau, alpha-synuclein, TDP-43 and NLRP3-ASC are in preclinical development. Together with the Company's SupraAntigen™-derived therapeutic antibody and vaccine candidates, AC Immune's comprehensive Morphomer™ pipeline enables a differentiated Precision Medicine approach against multiple key proteins by pairing the Company's targeted therapeutics with proprietary companion diagnostics.

Following the formal presentations, there will be an interactive virtual roundtable discussion between the audience and the AC Immune Management and Research and Development Teams.

To [register](#) for the webinar, please click [here](#).

### **Webinar Speakers**

*Andrea Pfeifer, Ph.D.*  
Chief Executive Officer  
AC Immune

*Marie Kosco-Vilbois, Ph.D.*  
Chief Scientific Officer  
AC Immune

*Sonia Poli, Ph.D.*  
Life Cycle Leader  
AC Immune

*Francesca Capotosti, Ph.D.*  
Group Leader, *In vivo* Pharmacology and Non-Clinical Safety  
AC Immune

### **About AC Immune SA**

AC Immune SA is clinical-stage biopharmaceutical company that aims to become a global leader in precision medicine for neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and NeuroOrphan indications driven by misfolded proteins. The Company's two clinically validated technology platforms, SupraAntigen™ and Morphomer™, fuel its broad and diversified pipeline of first- and best-in-class assets, which currently features nine therapeutic and three diagnostic candidates, six of which are currently in clinical trials. AC Immune has a strong track record of securing strategic partnerships with leading global pharmaceutical companies including Genentech, a member of the Roche Group, Eli Lilly and Company, and Janssen Pharmaceuticals, Inc., resulting in substantial non-dilutive funding to advance its proprietary programs and >\$3 billion in potential milestone payments.

### **For further information, please contact:**

#### **Head of Investor Relations**

Joshua Drumm, Ph.D.  
AC Immune  
Phone: +1 917 809 0814  
Email: [joshua.drumm@acimmune.com](mailto:joshua.drumm@acimmune.com)

#### **US Media**

Katie Gallagher  
LaVoie Health Science  
Phone: +1 617 792 3937  
Email: [kgallagher@lavoiehealthscience.com](mailto:kgallagher@lavoiehealthscience.com)

#### **European Investors & Media**

Chris Maggos  
LifeSci Advisors  
Phone: +41 79 367 6254  
Email: [chris@lifesciadvisors.com](mailto:chris@lifesciadvisors.com)

### **Forward looking statements**

This press release contains statements that constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune's strategies or expectations. In some cases, you can identify these statements by forward-looking words such as "may," "might," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "projects," "potential," "outlook" or "continue," and other comparable terminology. Forward-looking statements are based on management's current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions "Item 3. Key Information – Risk Factors" and "Item 5. Operating and Financial Review and Prospects" in AC Immune's Annual Report on Form 20-F and other filings with the Securities and Exchange Commission. These include: the impact of Covid-19 on our business, suppliers, patients and employees and any other impact of Covid-19. Forward-looking statements speak only as of the date they are made, and AC Immune does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.